<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051710</url>
  </required_header>
  <id_info>
    <org_study_id>CR176-17</org_study_id>
    <nct_id>NCT04051710</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH</brief_title>
  <acronym>QVR</acronym>
  <official_title>Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate Efficacy and Safety of Beclomethasone Dipropionate Metered Dose Inhaler (Inhalation Aerosol) (0.04mg/ INH) in Male and/ or Female Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurobindo Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurobindo Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the therapeutic equivalence of Beclomethasone Dipropionate MDI (Inhalation&#xD;
      Aerosol) 0.04 mg/ INH with the marketed QVAR® 40 mcg (Beclomethasone dipropionate&#xD;
      hydrofluoroalkane (HFA)) and to demonstrate superiority of both active treatments over&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to demonstrate the pharmacodynamic bioequivalence of the test product to the&#xD;
      reference product in terms of improvement in FEV1 measured before and after 4 weeks of&#xD;
      treatment in adult patients with chronic stable asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 From Pre Dose to End of Treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean change in Forced Expiratory volume in 1 second (FEV 1) from baseline to end of study visit</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1550</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>Group-I (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group-II (Reference)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group-III (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One inhalation of Placebo Inhalation Aerosol twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Product</intervention_name>
    <description>Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
    <arm_group_label>Group-I (Test)</arm_group_label>
    <other_name>Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Product</intervention_name>
    <description>Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
    <arm_group_label>Group-II (Reference)</arm_group_label>
    <other_name>QVAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Product</description>
    <arm_group_label>Group-III (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male or female subjects of non-childbearing or of childbearing potential&#xD;
             committing to consistent and correct use of an acceptable method of birth control.&#xD;
&#xD;
          2. Diagnosis of asthma as defined by the National Asthma Education and Prevention Program&#xD;
             at least 12 months prior to screening.&#xD;
&#xD;
          3. Pre-bronchodilator FEV1 of &gt;45% and &lt;85% of predicted value during the screening visit&#xD;
             and on the first day of treatment.&#xD;
&#xD;
          4. &gt;15% and &gt;0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of&#xD;
             albuterol inhalation (pMDI).&#xD;
&#xD;
          5. Patients should be stable on their chronic asthma treatment regimen for at least four&#xD;
             weeks prior to enrollment.&#xD;
&#xD;
          6. Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe&#xD;
             tobacco) within the past year, and having had &lt;10 pack-years of historical use.&#xD;
&#xD;
          7. Ability to replace current short-acting β agonist (SABAs) with salbutamol/albuterol&#xD;
             inhaler for use as needed for the duration of the study. Subjects should be able to&#xD;
             withhold all inhaled SABAs for at least six hours prior to lung function assessments&#xD;
             on study visits.&#xD;
&#xD;
          8. Ability to discontinue their asthma medications (inhaled corticosteroids and&#xD;
             long-acting β agonists) during the run-in period and for remainder of the study.&#xD;
&#xD;
          9. Willingness to give their written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life-threatening asthma, defined as a history of asthma episodes(s) requiring&#xD;
             intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic&#xD;
             seizures, asthma related syncopal episode(s), or hospitalizations within the past year&#xD;
             prior to the screening or during the run-in period.&#xD;
&#xD;
          2. Significant respiratory disease other than asthma (COPD, interstitial lung disease,&#xD;
             etc.)&#xD;
&#xD;
          3. Evidence or history of clinically significant disease or abnormality including&#xD;
             congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery&#xD;
             disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or&#xD;
             current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal,&#xD;
             or other diseases that, in the opinion of the investigator, would put the patient at&#xD;
             risk through study participation, or would affect the study analyses if the disease&#xD;
             exacerbates during the study.&#xD;
&#xD;
          4. Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle&#xD;
             ear infection within four weeks prior to the screening, during the run-in period, or&#xD;
             on the day of treatment.&#xD;
&#xD;
          5. Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or any inhaled,&#xD;
             intranasal, or systemic corticosteroid therapy.&#xD;
&#xD;
          6. Patients receiving β2-blockers, anti-arrhythmics, anti-depressants, and monoamine&#xD;
             oxidase inhibitors within 4 weeks prior to the screening.&#xD;
&#xD;
          7. Patients who required systemic corticosteroids (for any reason) within the past 2&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Marialouis</last_name>
    <role>Study Director</role>
    <affiliation>Aurobindo Pharma USA Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maharashtra Medical Foundation Joshi Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <results_first_submitted>October 22, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not decided</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04051710/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04051710/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group I (Test)</title>
          <description>One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.&#xD;
Test Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
        </group>
        <group group_id="P2">
          <title>Group II</title>
          <description>One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Reference) twice daily.&#xD;
Reference Product: QVAR® Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
        </group>
        <group group_id="P3">
          <title>Group III (Placebo)</title>
          <description>One inhalation of Placebo inhalation aerosol twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="620"/>
                <participants group_id="P2" count="620"/>
                <participants group_id="P3" count="310"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="616"/>
                <participants group_id="P2" count="612"/>
                <participants group_id="P3" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Group</title>
          <description>Subjects randomly enrolled into test group received test comparator, Beclomethasone dipropinate, 0.04 mg/INH to administer one inhalation twice daily</description>
        </group>
        <group group_id="B2">
          <title>Reference Group</title>
          <description>Subjects randomly enrolled into Reference group received Reference comparator, QVAR® containing Beclomethasone dipropinate, 0.04 mg/INH to administer one inhalation twice daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo Group</title>
          <description>Subjects randomly enrolled into Placebo group received a Placebo device to administer one inhalation twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="617"/>
            <count group_id="B2" value="615"/>
            <count group_id="B3" value="308"/>
            <count group_id="B4" value="1540"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="12.71"/>
                    <measurement group_id="B2" value="41.8" spread="12.85"/>
                    <measurement group_id="B3" value="40.6" spread="12.86"/>
                    <measurement group_id="B4" value="41.2" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="678"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="617"/>
                    <measurement group_id="B2" value="615"/>
                    <measurement group_id="B3" value="308"/>
                    <measurement group_id="B4" value="1540"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="617"/>
                    <measurement group_id="B2" value="615"/>
                    <measurement group_id="B3" value="308"/>
                    <measurement group_id="B4" value="1540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in FEV1 From Pre Dose to End of Treatment</title>
        <description>Mean change in Forced Expiratory volume in 1 second (FEV 1) from baseline to end of study visit</description>
        <time_frame>4 weeks</time_frame>
        <population>Mean change of FEV1 from baseline to end of study was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Group-I (Test)</title>
            <description>One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.&#xD;
Test Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
          </group>
          <group group_id="O2">
            <title>Group-II (Reference)</title>
            <description>One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.&#xD;
Reference Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
          </group>
          <group group_id="O3">
            <title>Group-III (Placebo)</title>
            <description>One inhalation of Placebo Inhalation Aerosol twice daily.&#xD;
Placebo: Placebo Product</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 From Pre Dose to End of Treatment</title>
          <description>Mean change in Forced Expiratory volume in 1 second (FEV 1) from baseline to end of study visit</description>
          <population>Mean change of FEV1 from baseline to end of study was measured</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="577"/>
                <count group_id="O2" value="566"/>
                <count group_id="O3" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.01"/>
                    <measurement group_id="O2" value="0.22" spread="0.01"/>
                    <measurement group_id="O3" value="0.09" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group I (Test)</title>
          <description>One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.&#xD;
Test Product: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
        </group>
        <group group_id="E2">
          <title>Group II (Reference)</title>
          <description>One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Reference) twice daily.&#xD;
Reference Product: QVAR® Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg</description>
        </group>
        <group group_id="E3">
          <title>Group III (Placebo)</title>
          <description>One inhalation of Placebo inhalation aerosol twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.1</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>white blood cells decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="619"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="620"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the ownership of all the data generated from the study and PI has no rights to publish the results or any information derived from the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph Marialouis</name_or_title>
      <organization>Aurobindo Pharma</organization>
      <phone>9196150585 ext 4013</phone>
      <email>jmarialouis@aurobindousa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

